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25 generic visual function instrument. RESULTS: Mean age 76.8
years: 55.8% women. All had wet age-related MD (often pro-
gressing rapidly to severe visual impairment). Strong correlations
between the 22 items (r > 0.50) and factor loadings >0.49 on a
forced one-factor analysis supported use of an overall weighted
impact score. Four subscales were indicated (Cronbach’s alpha
>0.7) measuring: essential tasks, family/social life, activities/capa-
bilities, and embarrassment. Patients with BE VA < 5/10 and WE
VA < 1/10 produced signiﬁcantly worse scores than those with
BE VA >= 5/10 and WE VA >= 1/10 (MacDQoL p < 0.0001; NEI-
VFQ-25 p < 0.0001; global scores). MacDQoL score variation
coefﬁcients were lower (better) than those of NEI-VFQ-25. CON-
CLUSIONS: The analysis conﬁrmed the metric properties of 
the MacDQoL.. The MacDQoL is associated with VA though, 
as expected, not as closely as the NEI-VFQ25 visual function
measure, but offers a broader individualised measure of the
impact of MD on QoL.
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OBJECTIVES: To quantify health-related quality-of-life and
utility in patients with ocular hypertension (OH) and primary
open-angle glaucoma (POAG). METHODS: A cross-sectional
survey was performed in 481 OH and POAG patients. Patients
were invited to complete a questionnaire at home. The ques-
tionnaire contained the EQ-5D, the Visual Functioning Ques-
tionnaire (VFQ-25, range 0–100 (best)) and the Glaucoma
Quality-of-Life questionnaire (GQL-15, range 0–75 (worst)).
Patients were also asked to report on demographics, treatment
history, treatment side-effects, and co-morbidities. Medical
records were consulted for clinical parameters of disease sever-
ity, such as optic nerve head excavation and visual ﬁeld loss.
RESULTS: Data-collection was ongoing at the time of writing.
The preliminary response rate is 79%. Here we report the results
of the ﬁrst 269 patients (56%) that participated. Mean age was
71.2 ± 10.4 years, 51% was male, and 91% was currently using
glaucoma medication. Trabeculectomy was self-reported in
13.8% of the patients. VFQ-25 score was 85.2 ± 14.9 in OH
patients (n = 110), 81.4 ± 15.5 in medically treated POAG
patients (n = 132) and 63.4 ± 23.4 in POAG patients with a
history of trabeculectomy (n = 27) (p < 0.001, unequal variance).
GQL-15 score was 21.8 ± 9.7, 23.6 ± 11.1 and 34.8 ± 13.4 in
these groups respectively (p < 0.001, unequal variance). EQ-5D
utility from the Dutch value set was 0.88 ± 0.18, EQ-5D VAS
was 75.9 ± 14.5; these values did not differ between groups. Pre-
liminary analyses with visual ﬁeld loss (Mean Deviation, n = 209)
in the better eye indicated no correlation with EQ-5D utility
(Spearman’s rho r = 0.1, ns) or EQ-5D VAS (r = 0.08, ns), and
weak correlations with VFQ-25 (r = 0.24, p < 0.001), and GQL-
15 (r = −0.23, p < 0.001). CONCLUSIONS: These preliminary
results indicate that vision-related quality-of-life is lower in more
severe glaucoma. Further research of the relationship between
disease severity and quality-of-life is currently being undertaken.
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OBJECTIVE: Restoration of near and far vision function
without recourse to spectacles remains a major goal of cataract
surgery. ReSTOR®, a new multi-focal IOL, addresses this issue
by improving both near and far vision without spectacles. The
present analysis attempts to quantify the vision beneﬁts experi-
enced by patients. METHODS: Data from two clinical trials con-
ducted in Europe and the United States, evaluating the safety and
efﬁcacy of ReSTOR® compared to a mono-focal IOL (MoF),
were pooled for an analysis of 672 patients undergoing cataract
extraction. The TyPE questionnaire was administered at base-
line, and after both ﬁrst-eye and second-eye surgery. The TyPE
measures 67 items evaluating distance and near vision limita-
tions, social activities, glare and halo problems, and patient sat-
isfaction both with and without spectacles. Principal components
analyses (PCA) of the TyPE questionnaire were performed at
baseline, and after ﬁrst-eye and second-eye surgery. Factorial
coordinates were compared both between ReSTOR® and MoF
(t-tests), and between visits (paired t-tests). RESULTS: The ﬁrst
PCA factor (F1) concerned limitations to overall visual function.
The second factor (F2) concerned vision limitations without
spectacles. Overall, signiﬁcant improvements of visual function
were seen between baseline and ﬁrst-eye surgery (p < 0.0001),
and between ﬁrst-eye and second-eye surgery (p < 0.0001). At
baseline, no signiﬁcant differences were observed between treat-
ment groups with respect to F1 or F2. Vision after ﬁrst-eye
surgery was signiﬁcantly better in the ReSTOR® group than the
MoF group on both factors (F1: p < 0.006; F2: p < 0.001). These
differences between ReSTOR® and MoF were maintained and
reinforced after second-eye surgery (F1: p < 0.001; F2: p <
0.001). CONCLUSIONS: Mono-focal and ReSTOR® IOLs
both improved visual function, but only ReSTOR® improved the
“vision without spectacles” factor because, of course, the mono-
focal does not correct near vision.
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OBJECTIVES: To describe the early development of a satisfac-
tion questionnaire for eye drops used in ocular hypertension and
glaucoma, developed in English and French simultaneously.
METHODS: A conceptual model of expectation and satisfaction
with eye drops was designed and used to guide patient (n = 15)
and clinician (n = 4) interviews in French and UK English. Fol-
lowing review of the interview responses, versions of the ques-
tionnaire were simultaneously developed in two languages and
then pilot-tested by six patients (three in France and three in 
the UK). RESULTS: After analysing the practitioners’ and the
patients’ interviews, six potential domains were identiﬁed as
having an impact on patients’ satisfaction regarding their eye
drop treatments. These domains are: 1) Patient characteristics
(16 items); 2) Treatment characteristics (4 items); 3) Relation-
ship between patient and practitioner (10 items); 4) Patients’ feel-
ings about their treatment (7 items); 5) Patients’ compliance (3
items); and 6) Interaction between the patient and the treatment
(six items). The questionnaire was developed using patients’ ver-
batim comments in each language. After a cognitive debrieﬁng
performed with six patients (six French and six English), the
wording and the domains of the questionnaire were conﬁrmed
in the two languages. CONCLUSION: The Eye Drops Satisfac-
tion Questionnaire (EDSQ) is now available in French and UK
English for use with patients receiving eye drops in ocular hyper-
